a full valuation allowance. 
(3) In 2024, we released $5.2 billion of our valuation allowance on our U.S. federal deferred tax assets. This is included on the 
change in valuation allowance line-item. 
The components of deferred tax assets and liabilities as of December 31, 2023 and 2024 are as follows (in millions): 
  As of December 31, 
  2023  2024 
Deferred tax assets     
Net operating loss carryforwards  $ 6,164   $ 4,319  
Research and development credits   1,275    1,539  
Stock-based compensation   66    71  
Accruals and reserves   440    730  
Accrued legal   120    221  
Fixed assets and intangible assets   4,135    3,500  
Lease liability   436    391  
Interest limitation carryforwards   876    760  
Capitalized research expenses   771    1,317  
Other   211    381  
Total deferred tax assets   14,494    13,229  
Less: Valuation allowance   (13,945)    (6,267)  
Total deferred tax assets, net of valuation allowance   549    6,962  
Deferred tax liabilities     
Investments   114    515  
ROU assets   301    270  
Other   18    14  
Total deferred tax liabilities   433    799  
Net deferred tax assets (liabilities)  $ 116   $ 6,163  
The income tax benefit was $5.8 billion for the year ended December 31, 2024, which includes a $6.4 billion benefit related to the 
release of our valuation allowance on the U.S. federal and state deferred tax assets, with the exception of our California R&D credits 
and other non-material deferred tax assets.